Tagged chimeric effector molecules and receptors thereof
The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated. For example, a T cell may be recombinantly modified for use in adoptive immunotherapy.
1. A single chain fusion protein comprising an extracellular component and an intracellular component connected by a transmembrane domain,
wherein the extracellular component comprises a scFv, a tag cassette having the amino acid sequence of SEQ ID NO.:1 or SEQ ID NO.:2, and a connector region comprising a hinge,
wherein the intracellular component comprises an effector domain,
and wherein:
(a) the tag cassette is comprised in the scFv; and/or
(b) the tag cassette is located amino-terminal to the scFv.
2. The single chain fusion protein of claim 1 , wherein the scFv comprises a first variable domain linked to a second variable domain by the amino acid sequence of SEQ ID NO.:45.
3. The single chain fusion protein of claim 1 , wherein the tag cassette is located amino-terminal to the scFv.
4. The single chain fusion protein of claim 1 , wherein the tag cassette is comprised in the scFv.
5. The single chain fusion protein of claim 1 , further comprising one or more tag cassettes located carboxy-terminal to the scFv.
6. The single chain fusion protein of claim 3 , further comprising one or more tag cassettes located carboxy-terminal to the scFv.
7. The single chain fusion protein of claim 4 , further comprising one or more tag cassettes located carboxy-terminal to the scFv.
8. The single chain fusion protein of claim 1 , wherein the scFv comprises a variable region linker, wherein the variable region linker comprises the tag cassette.
9. The single chain fusion protein of claim 1 , wherein the scFv comprises the amino acid sequence set forth in SEQ ID NO.:54.
10. The single chain fusion protein of claim 1 , comprising a plurality of tag cassettes, each of the plurality of tag cassettes independently having the amino acid sequence of SEQ ID NO.:1 or 2.
11. The single chain fusion protein of claim 1 , comprising a plurality of tag cassettes, wherein the plurality of tag cassettes comprises at least two different tag cassettes.
12. The single chain fusion protein of claim 1 , comprising:
one or more tag cassettes located amino-terminal to the scFv and one or more tag cassettes comprised in the scFv;
(ii) one or more tag cassettes located amino-terminal to the scFv and one or more tag cassettes comprised in the connector region; or (iii) one or more tag cassettes comprised in the scFv and one or more tag cassettes comprised in the connector region.
13. The single chain fusion protein of claim 1 , further comprising one or more tag cassettes:
(i) immediately amino-terminal to the connector region; and/or
(ii) interposed between and connecting linker modules.
14. The single chain fusion protein of claim 1 , wherein the scFv recognizes a target and the target comprises a tumor antigen, a B-cell target, a TNF receptor superfamily member, a Hedgehog family member, a receptor tyrosine kinase, a proteoglycan-related molecule, a TGF-β superfamily member, a Wnt-related molecule, a T-cell target, a dendritic cell target, an NK cell target, a monocyte/macrophage cell target, an angiogenesis target, a receptor protein, a cancer cell, a cell associated with an autoimmune disease or disorder, a cell associated with an inflammatory disease or disorder, an infectious organism or cell, a pathogen-specific molecule expressed on infected cells, CD3, CEACAM6, c-Met, EGFR, EGFRvIII, ErbB2, ErbB3, ErbB4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, FLT1, KDR, FLT4, CD44v6, CD151, CA125, CEA, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis A, Lewis Y, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, PSMA, RANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, HLA, tumor or pathogen associated peptide bound to HLA, hTERT peptide bound to HLA, tyrosinase peptide bound to HLA, WT-1 peptide bound to HLA, LTβR, LRP5, MUC1, OSMRβ, TCRα, TCRβ, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD81, CD86, CD123, CD171, CD276, B7H4, TLR7, TLR9, PTCH1, WT-1, Robo1, α-fetoprotein (AFP), Frizzled, OX40, or CD79b.
15. The single chain fusion protein of claim 1 , wherein the effector domain or an effector portion thereof is a 4-1BB (CD137), CD3ε, CD3δ, CD3ζ, CD25, CD27, CD28, CD79A, CD79B, CARD11, DAP10, FcRα, FcRβ, FcRγ, Fyn, HVEM, ICOS, Lck, LAG3, LAT, LRP, NKG2D, NOTCH1, NOTCH2, NOTCH3, NOTCH4, OX40 (CD134), ROR2, Ryk, SLAMF1, Slp76, pTα, TCRα, TCRβ, TRIM, Zap70, PTCH2, or any combination thereof.
16. The single chain fusion protein of claim 1 , wherein the effector domain or effector portion thereof comprises CD3ζ and one or more of 4-1BB (CD137), CD27, CD28, and OX40 (CD134).
17. The single chain fusion protein of claim 1 , wherein the fusion protein comprises from amino-terminus to carboxy-terminus:
(a) the tag cassette, the scFv, the connector region comprising (i) the hinge and (ii) one or more tag cassettes, the hydrophobic portion, and the intracellular component comprising the effector domain; or (b) the scFv, comprising a variable region linker disposed between a first variable region and a second variable region and containing the tag cassette, the connector region comprising (i) the hinge and (ii) one or more tag cassettes, the hydrophobic portion, and the intracellular component comprising the effector domain.
18. A nucleic acid molecule encoding a single chain fusion protein, wherein the single chain fusion protein comprises an extracellular component and an intracellular component connected by a transmembrane domain,
wherein the extracellular component comprises a scFv, a tag cassette having the amino acid sequence of SEQ ID NO.:1 or SEQ ID NO.:2, and a connector region comprising a hinge,
wherein the intracellular component comprises an effector domain,
and wherein:
(a) the tag cassette is comprised in the scFv; and/or
(b) the tag cassette is located amino-terminal to the scFv.
19. A vector comprising a nucleic acid molecule encoding a single chain fusion protein, wherein the single chain fusion protein comprises an extracellular component and an intracellular component connected by a transmembrane domain,
wherein the extracellular component comprises a scFv, a tag cassette having the amino acid sequence of SEQ ID NO.:1 or SEQ ID NO.:2, and a connector region comprising a hinge,
wherein the intracellular component comprises an effector domain,
and wherein:
(a) the tag cassette is comprised in the scFv; and/or
(b) the tag cassette is located amino-terminal to the scFv.
20. A host cell comprising a nucleic acid molecule encoding a single chain fusion protein, wherein the single chain fusion protein comprises an extracellular component and an intracellular component connected by a transmembrane domain,
wherein the extracellular component comprises a scFv, a tag cassette having the amino acid sequence of SEQ ID NO.:1 or SEQ ID NO.:2, and a connector region comprising a hinge,
wherein the intracellular component comprises an effector domain,
and wherein:
(a) the tag cassette is comprised in the scFv; and/or
(b) the tag cassette is located amino-terminal to the scFv.
21. The host cell of claim 20 , wherein the host cell is a T cell.
22. The host cell of claim 21 , wherein the host cell is a virus-specific T cell, a tumor antigen specific cytotoxic T cell, a naïve T cell, a memory stem T cell, a central or effector memory T cell, a CD4+ CD25+ regulatory T cell, a mature T cell, a CD8+ T cell, or a CD4+ T cell.
23. A method comprising contacting a cell comprising the single chain fusion protein of claim 1 with a binding domain specific for the tag cassette.
24. A method of treating a disease in a subject, the method comprising administering to the subject a host cell of claim 20 , wherein the disease is associated with expression of a target recognized by the scFv.
25. The method of claim 24 , wherein the disease is a viral, bacterial, cancer, inflammatory, immune, or aging-associated disease.